Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medipharm Labs Corp (OP:MEDIF)

0.0473 -0.0014 (-2.87%)
Streaming Delayed Price Updated: 9:38 AM EDT, Apr 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Medipharm Labs Corp

< Previous 1 2 Next >
News headline image
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs to Enter New Market with Costa Rica Supply Agreement
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Completes First Shipment to France
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Announces Complete Dismissal of Defamation Action Initiated by Apollo, Nobul and Regan McGee Under Ontario Anti-SLAPP Law
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis Gains
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Sets Date to Report Third Quarter 2025 Financial Results
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Sets Date to Report Second Quarter 2025 Financial Results
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Announces Voting Results from the 2025 Annual and Special Meeting of Shareholders
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Cautions Shareholders To Await Final Results of Annual and Special Meeting
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
Apollo Capital Wins Proxy Contest at MediPharm Labs
From Apollo Technology Capital Corporation
Via GlobeNewswire
News headline image
Leading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Reminds Shareholders to Vote in Advance of June 13 Deadline
Shareholders Urged to Vote for Proven Strategy and Team, Reject Dissident’s Inadequate Plan and Nominees 
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
Apollo Capital Releases Investor Presentation Highlighting Plan to Make MediPharm Labs the World’s Leading International Medical Cannabis Company
From Apollo Technology Capital Corporation
Via GlobeNewswire
News headline image
MediPharm Labs Closes $4.5 Million Sale of Hope, BC Facility and Announces Plans to Expand EU GMP Cultivation Capacity at Napanee Facility
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo’s Arguments and Director Slate
ISS concludes that Apollo “has not presented a compelling case for change” 
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital
From Apollo Technology Capital Corporation
Via GlobeNewswire
News headline image
MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
Alleged Securities Fraud at MediPharm Labs Says Apollo Capital
From Apollo Technology Capital Corporation
Via GlobeNewswire
News headline image
MediPharm Labs Board Issues Letter to Shareholders in Response to Inadequate Dissident Plan
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
Apollo Capital Calls Out MediPharm Chairman Chris Taves (Managing Director, BMO Capital Markets) for Failure to Properly Communicate to Shareholders Details of David Pidduck’s Past as CEO and VP of Marketing for OxyContin® Manufacturer Purdue Pharma
From Apollo Technology Capital Corporation
Via GlobeNewswire
News headline image
MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd.
From MediPharm Labs Corp.
Via GlobeNewswire
News headline image
Apollo Capital Comments on MediPharm Labs’ Failure to Respond to Reasonable Offer to Ensure Fair, Lawful and Transparent 2025 Annual Meeting
From Apollo Technology Capital Corporation
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.